ShapeShapeauthorShapechevroncrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShaperssShape

Boehringer Ingelheim Animal Health launches vaccine to protect poultry from three diseases

9 October 2020, at 8:00am

VAXXITEK® HVT+IBD+ILT is the first vaccine to offer protection in one shot from Infectious Laryngotracheitis, Marek’s Disease and Infectious Bursal Disease

Boehringer Ingelheim Animal Health launched an innovative, first-of-its-kind vaccine in the United States today to protect poultry from three diseases.

VAXXITEK® HVT+IBD+ILT is the first vaccine to offer protection in one shot from Infectious Laryngotracheitis, Marek’s Disease and Infectious Bursal Disease (classic and variant types).

“This new trivalent vaccine provides a strong immune foundation, optimizes protection for flocks and offers reliable protection,” said Matt Nelson, who leads Boehringer Ingelheim Animal Health’s U.S. poultry business.

The three-in-one vaccine is the latest addition in the VAXXITEK® family of vaccines for poultry. It uses the same bioengineering platform as VAXXITEK® HVT+IBD, which has protected more than 100 billion birds from Marek’s Disease and Infectious Bursal Disease in more than 75 countries since its introduction in 2006.

Infectious Laryngotracheitis (ILT) is an acute viral respiratory disease in poultry caused by Gallid herpesvirus type 1. There is no effective treatment for ILT, and the virus persists in affected birds for life. The disease can cause major economic losses.

An existing, non-vectored vaccine from Boehringer Ingelheim Animal Health protects against ILT. The new trivalent is a vectored vaccine that provides protection against ILT along with two other health threats for poultry: Marek’s Disease and Infectious Bursal Disease.

The company will manufacture its new vaccine in Gainesville, Georgia, where it makes 60 billion doses of poultry vaccine a year for use in the United States and about 60 other countries.

After launching in the United States, Boehringer Ingelheim Animal Health plans to seek regulatory approval to offer VAXXITEK® HVT+IBD+ILT in other countries.